コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 nd therapy outside a health-care setting for paroxysmal supraventricular tachycardia.
2 inded study drug for an episode of perceived paroxysmal supraventricular tachycardia.
3 tiate atrial tachycardia from other forms of paroxysmal supraventricular tachycardia.
4 f 14 (52%) patients developed 38 relapses of paroxysmal supraventricular tachycardia in the ICU after
5 with 1:1 ventriculoatrial conduction during paroxysmal supraventricular tachycardia is a useful diag
6 suggests that the mechanism responsible for paroxysmal supraventricular tachycardia is atrial reentr
8 atures and pacing maneuvers in patients with paroxysmal supraventricular tachycardia (PSVT) in the el
9 he epidemiology and clinical significance of paroxysmal supraventricular tachycardia (PSVT) in the ge
11 son safety and efficacy during conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus
12 in patients with documented but noninducible paroxysmal supraventricular tachycardia (PSVT) who have
14 association with AP-affiliated arrhythmias: paroxysmal supraventricular tachycardia (PSVT), atrial f
16 kinson-White syndrome, recurrent episodes of paroxysmal supraventricular tachycardia (SVT) were analy
17 his approach could empower patients to treat paroxysmal supraventricular tachycardia themselves outsi
18 he primary endpoint of time to conversion of paroxysmal supraventricular tachycardia to sinus rhythm
19 nversion of atrioventricular-nodal-dependent paroxysmal supraventricular tachycardia to sinus rhythm
20 nversion of atrioventricular-nodal-dependent paroxysmal supraventricular tachycardia to sinus rhythm.
21 aged at least 18 years and had a history of paroxysmal supraventricular tachycardia with sustained,
22 dy drug for atrioventricular-nodal-dependent paroxysmal supraventricular tachycardia, with diagnosis